Novozymes A/S (OTCMKTS:NVZMY) Short Interest Update

Novozymes A/S (OTCMKTS:NVZMY – Get Free Report) was the recipient of a large decrease in short interest during the month of May. As of May 29th, there was short interest totaling 12,291 shares, a decrease of 60.1% from the May 14th total of 30,830 shares. Based on an average trading volume of 83,894 shares, the days-to-cover ratio is currently 0.1 days. Approximately 0.0% of the shares of the stock are short sold.

Novozymes A/S Trading Down 0.4%

Shares of OTCMKTS NVZMY traded down $0.23 during mid-day trading on Friday, hitting $59.76. The company’s stock had a trading volume of 23,466 shares, compared to its average volume of 48,196. The stock has a market cap of $24.77 billion, a price-to-earnings ratio of 40.38, a price-to-earnings-growth ratio of 1.12 and a beta of 0.95. The company has a debt-to-equity ratio of 0.27, a current ratio of 1.67 and a quick ratio of 1.03. Novozymes A/S has a one year low of $49.90 and a one year high of $75.99. The company’s fifty day simple moving average is $59.39 and its 200-day simple moving average is $60.41.

Get Novozymes A/S alerts:

Novozymes A/S (OTCMKTS:NVZMY – Get Free Report) last issued its earnings results on Tuesday, May 5th. The biotechnology company reported $0.51 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.82 by ($0.31). The business had revenue of $1.31 billion during the quarter, compared to the consensus estimate of $1.32 billion. Novozymes A/S had a net margin of 14.22% and a return on equity of 6.52%. On average, sell-side analysts anticipate that Novozymes A/S will post 2.43 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities research analysts have commented on NVZMY shares. Zacks Research raised shares of Novozymes A/S from a “strong sell” rating to a “hold” rating in a report on Monday, June 8th. Rothschild & Co Redburn raised shares of Novozymes A/S to a “strong-buy” rating in a report on Friday, March 27th. Finally, Kepler Capital Markets raised shares of Novozymes A/S from a “hold” rating to a “strong-buy” rating in a report on Wednesday, May 13th. Two equities research analysts have rated the stock with a Strong Buy rating and one has given a Hold rating to the company’s stock. According to data from MarketBeat, Novozymes A/S presently has a consensus rating of “Buy”.

Get Our Latest Stock Analysis on NVZMY

About Novozymes A/S

(Get Free Report)

Novozymes A/S is a Danish biotechnology company that develops, produces and markets industrial enzymes and microorganisms. Headquartered in Bagsværd, Denmark, the company focuses on using biological solutions to improve industrial processes across a range of end markets. Its offerings are designed to increase product performance or process efficiency while reducing energy, water and chemical consumption for customers.

The company’s product portfolio includes enzymes and microbial solutions for household care (detergents and cleaning products), food and beverages (baking, brewing and dairy applications), bioenergy (enzymes for biofuel production), agriculture (microbial crop inputs and biocontrols) and industrial processing (textiles, pulp and paper, and wastewater treatment).

Featured Stories

• Five stocks we like better than Novozymes A/S
• 3 ETFs Giving Ready-Made Access to the Discounted International Small-Cap Space
• What to Expect From Q2 Earnings as Tech Strength Broadens
• Viasat’s Orbiting Profits: Space Force Jackpot?
• Robinhood Wants a Bigger Role in IPOs—Here’s Why It Matters

Receive News & Ratings for Novozymes A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novozymes A/S and related companies with MarketBeat.com's FREE daily email newsletter.